文献速递间质性肺疾病

利妥昔单抗联合霉酚酸酯治疗间质性肺病:EVER-ILD双盲随机安慰剂对照试验

Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.
PubMed 文献 · Eur Respir J · 2023-06-08

EVER-ILD试验纳入122例NSIP型间质性肺病患者,随机接受利妥昔单抗或安慰剂联合霉酚酸酯治疗6个月。利妥昔单抗组FVC%预计值变化优于安慰剂组(组间差3.60,95%CI 0.41-6.80,P=0.0273),无进展生存期亦更优(HR 0.47,95%CI 0.23-0.96,P=0.03),但需注意病毒感染风险。

要点

  • 利妥昔单抗联合MMF较单用MMF改善6个月FVC%预计值变化。
  • 联合组无进展生存期更优,严重不良事件两组相近。
  • 联合组报告9例感染,其中3例为病毒感染,需警惕。

核心结论

  • 在NSIP型ILD患者中,利妥昔单抗联合MMF优于单用MMF,但使用联合方案须考虑病毒感染风险。

研究设计与样本

  • 随机、双盲、两平行组、安慰剂对照试验(NCT02990286),纳入 connective tissue disease-associated ILD 或 idiopathic interstitial pneumonia(伴或不伴自身免疫特征)且呈NSIP模式的患者。
  • 122例随机患者接受至少一剂利妥昔单抗(n=63)或安慰剂(n=59),1:1随机,在第1天和第15天给予利妥昔单抗1000 mg或安慰剂,并联合MMF 2 g/日治疗6个月。

主要发现

  • FVC%预计值从基线至6个月的最小二乘均值变化:利妥昔单抗+MMF组+1.60(SE 1.13),安慰剂+MMF组-2.01(SE 1.17),组间差3.60(95%CI 0.41-6.80;P=0.0273)。
  • 无进展生存期在利妥昔单抗+MMF组更优(粗风险比0.47,95%CI 0.23-0.96;P=0.03)。
  • 严重不良事件:利妥昔单抗+MMF组26例(41%),安慰剂+MMF组23例(39%)。
  • 感染:利妥昔单抗+MMF组报告9例感染(5例细菌、3例病毒、1例其他),安慰剂+MMF组报告4例细菌感染。

临床怎么用

  • 对于NSIP型ILD患者,可考虑利妥昔单抗联合MMF治疗以改善肺功能并降低进展风险。
  • 联合治疗期间应监测病毒感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Standard of care for interstitial lung disease (ILD) with a nonspecific interstitial pneumonia (NSIP) pattern proposes mycophenolate mofetil (MMF) as one of the first-step therapies while rituximab is used as rescue therapy. METHODS: In a randomised, double-blind, two-parallel group, placebo-controlled trial (NCT02990286), patients with connective tissue disease-associated ILD or idiopathic interstitial pneumonia (with or without autoimmune features) and a NSIP pattern (defined on NSIP pathological pattern or on integration of clinicobiological data and a NSIP-like high-resolution computed tomography pattern) were randomly assigned in a 1:1 ratio to receive rituximab (1000 mg) or placebo on day 1 and day 15 in addition to MMF (2 g daily) for 6 months. The primary end-point was the change in percent predicted forced vital capacity (FVC) from baseline to 6 months analysed by a linear mixed model for repeated measures analysis. Secondary end-points included progression-free survival (PFS) up to 6 months and safety. FINDINGS: Between January 2017 and January 2019, 122 randomised patients received at least one dose of rituximab (n=63) or placebo (n=59). The least-squares mean change from baseline to 6 months in FVC (% predicted) was +1.60 (se 1.13) in the rituximab+MMF group and -2.01 (se 1.17) in the placebo+MMF group (between-group difference 3.60, 95% CI 0.41-6.80; p=0.0273). PFS was better in the rituximab+MMF group (crude hazard ratio 0.47, 95% CI 0.23-0.96; p=0.03). Serious adverse events occurred in 26 (41%) patients of the rituximab+MMF group and in 23 (39%) of the placebo+MMF group. Nine infections were reported in the rituximab+MMF group (five bacterial infections, three viral infections, one other) and four bacterial infections in the placebo+MMF group. INTERPRETATION: Combination of rituximab and MMF was superior to MMF alone in patients with ILD and a NSIP pattern. The use of this combination must take into consideration the risk of viral infection.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Mankikian J, Caille A, Reynaud-Gaubert M, et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2023. PMID: 37230499. doi:10.1183/13993003.02071-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。